[PREMIUM ALERT] 3/9 Red Hot Early-Stage (NASDAQ) Pharma Stock with 145% Upside Potential!

[Premium Alert] for 3/9 (NASDAQ) Scores Major Milestone! Transitions to Revenue Generating Company Lucy Scientific Discovery, Inc. (Ticker: LSDI) CATALYST: Transitions To Revenue Generating Company 10XProTrader Member, Good morning, make sure you set yourself a reminder that the market opens in approx. 2.5 hours from now. This is Kevin Vander with “10XProTrader” delivering you your new premium alert for Thursdays 3/9 - trading session which is Lucy Scientific Discovery, Inc.(NASDAQ: LSDI) priced just under $2.00/share. There are NO bigger catalysts than when a stock releases news about their Revenue increase! Immediately turn your attention to Lucy Scientific Discovery, Inc.(NASDAQ: LSDI). Researching Developing & Manufacturing Psychotropic Drugs Need proof that Lucy Scientific Discovery, Inc. (NASDAQ: LSDI) is an under-the-radar company in one of the hottest sectors in the market? Then, consider this. The company recently announced game-changing news scoring a major milestone by securing its first commercial sale of the psychedelic compound psilocybin. You are finding out this news much before the rest of Wall Street ever takes notice! Another discovery done well by 10XProTrader... One Tiny Company Has Positioned Itself To Dominate The Manufacturing & Research of Psychotropic Drugs About Lucy Scientific Discovery Inc. website: www.lucyscientific.com Lucy Scientific Discovery Inc. [NASDAQ:LSDI] an early-stage psychedelics manufacturing company that is focused on becoming the premier research, development, and manufacturing organization for the emerging psychedelics-based medicines industry. Lucy maintains a Controlled Drugs and Substances Dealer's License under Part J of the Food and Drug Regulations promulgated under the Food and Drugs Act (Canada), more commonly known as a Dealer's License, that was issued to Lucy by Health Canada's Office of Controlled Substances. This Dealer's License authorizes the Company to develop, sell, deliver, and manufacture (through extraction or synthesis) certain pharmaceutical-grade active pharmaceutical ingredients, or APIs, used in controlled substances and their raw material precursors. This Stock is an absolute Game-Changer for Investors. How High Could The Share Price of (LSDI) Sky-Rocket Too? Considering that while the (LSDI) value proposition was already compelling, news of the sale transformed them from a pre-revenue company to a revenue-generating one. That alone is worthy of rally hats; although that didn't happen, there is a silver lining. For those getting turned on to the LSDI story now, and knowing that history tends to repeat, the best days for this NASDAQ-traded company are likely ahead. As in the near term. A Sector Worthy Of Front Page Headlines Keep in mind that while not catching front-page headlines, the psychedelics sector is certainly earning plenty of media attention. In fact, Lucy Scientific was recently featured on FOX News Varney & Company, where the CFO highlighted how his company and the industry are already targeting treatment opportunities expected to eclipse $6.4 billion before the decade's end. And for many analysts, that expectation is extremely low. Many taking a broader perspective of using psychedelics to treat mental and addiction disorders put the opportunity well beyond $30 billion, with Alcohol Use Disorder treatment opportunities alone potentially earning the lion's share of that potential. Then, after factoring in potential use applications to treat depression, anxiety, and PTSD, even that $30 billion estimate could miss the mark by a significant multiple. Being Early To This Trade Is Critical In other words, being early to this investment proposition matters. Remember, when CBD hit the market, a majority of the population and legislators scoffed at the idea of its legalized use. Fast forward a decade later, and it's mainstream. And with big pharma companies like Pfizer (NYSE: PFE) and Johnson & Johnson (NYSE: JNJ) already entrenched in the psychedelics space, psychedelic-based therapeutics will likely follow a similar path toward mainstream use and regulatory approval. Wise To Pay More For Real Value Still, investors like yourself need to be prudent. In the early part of the decade, any company with a fancy ticker associated with CBD was earning tremendous investor interest. They found out the hard way, financially, that not all companies in emerging sectors are created equal. Many popular and so-called sector players didn't even have a foot in the revenue-generating door. Of course, that led to significant losses for those investors chasing penny stock names instead of sometimes paying only a small amount more to get exposure to an emerging sector with a company presenting an actual market position and potential. Expect the same to happen in the psychedelics space. But this time, investors may benefit from lessons learned. If so, they would pay more attention to revenue-generating companies like LSDI and less to the conceptual stage companies more likely to bust than boom. Recent game-changing news from LSDI puts them in the camp of the latter. Moreover, it separates them into a small group of companies that are actually generating revenue in what could be one of the most significant investment opportunities since the early days of EV and CBD. The #1 Catalyst That Creates Enormous Upside Potential Specifically, Lucy Scientific announced an agreement leading to its first commercial sale of psilocybin to the prestigious Hadassah BrainLabs - Center for Psychedelics Research, Hadassah Medical Center, Hebrew University, Jerusalem, Israel. As mentioned, the initial commercial sale of psilocybin marks more than a key operational milestone for LSDI; it transforms them into a revenue-generating company and further establishes its ability and role to supply the global psychedelic community with compounds and services. Moreover, the sale strengthens LSDI's relationship with the researchers at Hadassah-Hebrew University Medical Center, whose research is helping prove the academic foundations supporting the potential of psychedelics to improve the lives of millions of people worldwide. Lucy Scientific Discovery, Inc. Is No Newbie To The Space This is important to note. While the deal announced results in its first commercial sale, LSDI is no newbie to the sector. Lucy has previously provided naturally-derived N.N-dimethyltryptamine (DMT) to the Israel-based Brain Lab and Biological Psychiatry Department at Hadassah-Hebrew University. Data from studies using the provided material is expected to be published soon. In other words, a second milestone is in the crosshairs for LSDI investors. And more are likely to follow, considering that LSDI has been actively involved in that center's studies by providing a variety of psychedelic compounds which have been instrumental in advancing their scientific understanding and opening new avenues for discovery. That's not a bullish embellishment. Those are the paraphrased words of Dr. Bernard Lerer, Professor of Psychiatry and Director of Hadassah BrainLabs. But his accolades are just one part of the LSDI value proposition. Lucy Scientific Discovery, Inc. Uniquely Licensed In Canada As a research, development, and manufacturing company in the psychedelics-based medicine space, Lucy Scientific Discovery exudes near and long-term potential from being granted a Controlled Drugs and Substances Dealer's License under Part J of the Food and Drug Regulations promulgated under the Food and Drugs Act (Canada), more commonly known as a Dealer's License, that was issued by Health Canada's Office of Controlled Substances. The inherent value there, beyond LSDI being one of the few known companies holding such a license in Canada, is that it uniquely authorizes them to develop, sell, deliver, and manufacture (through extraction or synthesis) certain pharmaceutical-grade active pharmaceutical ingredients used in controlled substances and their raw material precursors. In other words, LSDI is years ahead of most in the competitive landscape. So much so that they may be the most helpful vehicle for other companies, even those competing in some respects, to advance their own clinical initiatives. And that could happen sooner than later. Remember, it's not a matter of "if" but of "when" psychedelics go mainstream. Even the perception of psychedelics use in the counter-cultural fad of the 1960s is receding, replaced by the expected value that these treatment alternatives can add to 2020's medicine. Expectations of their value are high, noted by the number of psychedelic pharmaceutical companies already in clinical-stage programs evaluating treatment candidates, some even challenging their own traditional drug contributions to treat depression, addiction, and schizophrenia, recognizing the potential benefits of the compounds without the severe side effects and risks associated with conventional prescription medicines. Lucy Scientific Discovery, Inc. Is Undervalued Considering The Sum Of Its Parts Here's more excellent news to strongly consider. The playing field includes more than only big pharma. Atai Life Sciences (NASDAQ: ATAI) and Compass Pathway (NASDAQ: CMPS), which currently boast $273.6 million and $353.8 million market caps, respectively, are also helping to blaze new trails of treatment. But here's the disconnect about those valuations. They are roughly 4X and 9X higher than LSDIs. That exposes at least two things. Investors appreciate the potential of those two companies, and LSDI appears significantly undervalued. That case is supported by LSDI having a type of license many may need. Remember, its manufacturing license is an asset with intrinsic and inherent value. In fact, companies wanting to access Canadian research opportunities may need their help to secure GMP manufacturing requirements, including those mentioned. ATAI is evaluating using ibogaine and ketamine to develop multiple drugs targeting various indications. And Compass is focused on the value of psilocybin as the lead in its lead drug candidate. Others, like Cybin (NYSE: CYBN) and Mind Medicine (NASDAQ: MNMD), with market caps under $150 million today, are advancing studies as well, testing the value of psychedelic substances for separate indications. In other words, there's plenty of opportunity for LSDI to capitalize on its own needs and those of others. Lucy Scientific Discovery, Inc. An Opportunity Exposed Thus, with a NASDAQ listing providing credibility and assuring transparency, a valuable Health Canada license, and a management team able to execute on every level of product and market development, investors would be wise to look for under-the-radar investment opportunities over those where a premium is already priced in. Lucy Scientific Discovery checks those boxes and, at the same time, has mitigated downside risk by holding valuable and exclusive assets. In addition, after completing its recent public offering, LSDI can capitalize on opportunities with a balance sheet able to fund near-term objectives. All told, Lucy Scientific Discovery (LSDI) is a $2.00 stock with enormous near and long-term potential. And its move from a pre-revenue to a revenue-generating company this week proves it's not taking its time to maximize the value of its relationships and assets. With that change no longer a presumption but a fact, taking advantage of LSDI at current levels may present more than a ground-floor opportunity; it may be one too good to ignore. Pay close attention to your inbox and cell for my next update coming on this once-in-a-lifetime trade. Kevin Vander Publisher, 10XProTrader.com Investment Research Sources: Leg∙al Entity Information: 10XProTrader is a website owned and operated by 10XPublishing, LLC., which is a DBA of 10XMedia, LLC. You are receiving this e-mail as part of your subscription to 10XProTrader. Please do not reply to this e-mail as this address is not monitored. Help line: Customer service number is 1-800-803-4811 Mailing Address: Attn: Member Services | 10XMedia, LLC. 340 Royal Poinciana Way Suite 317-#409 Palm Beach, FL 33480 Our Customer Service team is available Monday - Friday between 9:00 AM and 5:00 PM ET. © 2023 10XMedia, LLC. All Rights Reserved. Nothing in this email should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular inves∙tment situation. N∙o communication by our employees to you should be deemed as personalized financial advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers. © 2023 10XProTrader.com, All Rights Reserved. 10XProTrader is a financial publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or investment for any specific individual. This communication is a paid advertisement. 10XProTrader.coms is owned and operated by 10XMedia LLC, which is a Florida based Limited Liability Company and/or its subsidiaries and/or affiliates ("Company," "we," or "us") have been compensated $20,000 USD to disseminate this communication. Please review the full disc∙laimer at [( for important information about this advertisement. © 2022 10XProTrader. All rights reserved., 340 Royal Poinciana Way Suite 317, 33480, Palm Beach, United States You may [unsubscribe]( or [change your contact details]( at any time.